Should You Buy VKTX Stock Amid Renewed M&A Speculations?

Shares of Viking Therapeutics (VKTX) rose nearly 8% on Friday after several third-party reports suggested that it was being eyed for a potential takeover by pharma giant Pfizer (PFE) . These reports even suggest that PFE has appointed Morgan Stanley as its advisor on the transaction.Viking is one of the few biotech stocks that has shown immense potential in the obesity space. It is developing VK2735, an investigational novel dual GLP-1 and GIP receptor agonist, in different clinical studies as oral and subc ...